title: Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against Toxoplasma chronic infection in mice.
abstract: To investigate the vaccine potential of both the Toxoplasma GRA2 and GRA6 antigens, the full length recombinant proteins were produced in Escherichia coli, formulated in MPL adjuvant, and used alone and in combination ("mix"), to immunize CBA/J mice. Although high ratios of specific IgG2a/IgG1 were measured against both proteins, only spleen cells from GRA2-immunized mice and mix-immunized mice produced high amounts of both IFN-gamma and IL-2 upon induction with Toxoplasma gondii Excretory-Secretory Antigens. Intra peritoneal challenge with Toxoplasma cysts resulted in significant reduction of brain cysts in GRA2- and in mix-vaccinated mice only. This study shows the protective efficacy of recombinant GRA2 against chronic infection by T. gondii and confirms the utility of MPL adjuvant in enabling a vaccine candidate to induce a protective Th1 immune response.
authors.affiliation: CNRS UMR 5163 - Université Joseph Fourier, UFR de Biologie, Institut Jean Roget, Campus Santé, Domaine de la Merci. BP 170, 38042 Grenoble cedex 09, France.
authors.forename: Majid
authors.initials: M
authors.lastname: Golkar
authors.forename: Mohammad-Ali
authors.initials: MA
authors.lastname: Shokrgozar
authors.forename: Sima
authors.initials: S
authors.lastname: Rafati
authors.forename: Karine
authors.initials: K
authors.lastname: Musset
authors.forename: Mehdi
authors.initials: M
authors.lastname: Assmar
authors.forename: Reza
authors.initials: R
authors.lastname: Sadaie
authors.forename: Marie-France
authors.initials: MF
authors.lastname: Cesbron-Delauw
authors.forename: Corinne
authors.initials: C
authors.lastname: Mercier
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D000953:Antigens, Protozoan / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification; D001921:Brain / Q000469:parasitology; D016207:Cytokines / Q000276:immunology; D004195:Disease Models, Animal; D004926:Escherichia coli / Q000235:genetics; D006801:Humans; D008050:Lipid A / Q000031:analogs & derivatives* / Q000276:immunology; D051379:Mice; D008808:Mice, Inbred CBA; D015800:Protozoan Proteins / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification; D016052:Protozoan Vaccines / Q000276:immunology*; D018417:Th1 Cells / Q000276:immunology; D014122:Toxoplasma / Q000276:immunology; D014124:Toxoplasmosis, Animal / Q000276:immunology / Q000517:prevention & control*; D022223:Vaccines, Subunit / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification
chemical_list: D000276:Adjuvants, Immunologic; D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D016207:Cytokines; C095047:GRA6 protein, Toxoplasma gondii; C106990:Gra2 protein, Toxoplasma gondii; D008050:Lipid A; D015800:Protozoan Proteins; D016052:Protozoan Vaccines; D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic; C048436:monophosphoryl lipid A